Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)
China · Delayed Price · Currency is CNY 40.80
+1.42 (3.61%)
Jul 31, 2026, 3:00 PM CST
SHA:688336 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 36,566 | 36,742 | 13,212 | 13,884 | 7,833 | 11,431 | |
Market Cap Growth | 10.96% | 178.10% | -4.84% | 77.24% | -31.47% | -24.75% |
Enterprise Value | 34,303 | 34,978 | 11,916 | 12,009 | 5,381 | 8,997 |
Last Close Price | 40.80 | 40.75 | 14.63 | 15.30 | 8.63 | 12.61 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 12.36 | 12.67 | 18.75 | 47.13 | 158.90 | 632.98 |
Forward PE | 56.88 | 111.00 | 36.46 | 72.21 | 100.10 | 58.82 |
PS Ratio | 8.47 | 8.75 | 11.07 | 13.69 | 9.49 | 12.31 |
PB Ratio | 4.26 | 4.37 | 2.39 | 2.85 | 1.70 | 2.52 |
P/TBV Ratio | 4.40 | 4.46 | 2.47 | 2.98 | 1.78 | 2.63 |
P/FCF Ratio | 14.47 | 13.17 | 37289.16 | 76.87 | 640.46 | - |
P/OCF Ratio | 13.10 | 12.07 | 46.99 | 33.35 | 33.55 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 7.94 | 8.33 | 9.98 | 11.84 | 6.52 | 9.69 |
EV/EBITDA Ratio | 10.02 | 10.78 | 35.62 | 41.80 | 63.38 | 337.42 |
EV/EBIT Ratio | 10.39 | 11.21 | 57.68 | 62.80 | - | - |
EV/FCF Ratio | 13.57 | 12.54 | 33631.43 | 66.49 | 439.99 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | - | - | 0.01 | 0.01 | 0.03 | - |
Debt / EBITDA Ratio | - | - | 0.15 | 0.17 | 1.77 | - |
Debt / FCF Ratio | - | - | 141.19 | 0.28 | 12.27 | - |
Net Debt / Equity Ratio | -0.26 | -0.68 | -0.39 | -0.37 | -0.53 | -0.52 |
Net Debt / EBITDA Ratio | -0.67 | -1.77 | -6.53 | -6.37 | -28.58 | -88.73 |
Net Debt / FCF Ratio | -0.88 | -2.06 | -6163.12 | -10.14 | -198.44 | 4.66 |
Asset Turnover | 0.58 | 0.56 | 0.21 | 0.20 | 0.17 | 0.19 |
Inventory Turnover | 1.31 | 1.36 | 1.44 | 1.06 | 0.94 | 0.97 |
Quick Ratio | 9.14 | 13.22 | 7.51 | 6.54 | 7.27 | 12.18 |
Current Ratio | 21.99 | 13.94 | 8.39 | 7.30 | 7.96 | 13.33 |
Return on Equity (ROE) | 41.75% | 41.45% | 13.28% | 5.98% | 0.99% | -0.04% |
Return on Assets (ROA) | 26.81% | 26.14% | 2.29% | 2.30% | -0.47% | -1.38% |
Return on Invested Capital (ROIC) | 62.20% | 90.44% | 6.31% | 6.68% | -1.73% | -5.53% |
Return on Capital Employed (ROCE) | 37.10% | 36.70% | 3.70% | 3.80% | -0.80% | -2.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 8.13% | 7.89% | 5.33% | 2.12% | 0.63% | 0.16% |
FCF Yield | 6.91% | 7.60% | 0.00% | 1.30% | 0.16% | -4.44% |
Dividend Yield | 0.82% | 0.82% | 0.58% | 0.22% | - | - |
Payout Ratio | 2.56% | 2.64% | 7.43% | 0.50% | 2.48% | - |
Buyback Yield / Dilution | -0.65% | -0.24% | -0.69% | 0.34% | -2.37% | -2.38% |
Total Shareholder Return | 0.20% | 0.58% | -0.11% | 0.56% | -2.37% | -2.38% |